A STUDY OF 50 PACIENTS WITH POLYCYTHEMIA INDUCED BY SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS

EHA Library, Fernando Vázquez Lagos, 421637

ABSENCE OF QTC PROLONGATION WITH RUSFERTIDE, A HEPCIDIN MIMETIC FOR THE TREATMENT OF POLYCYTHEMIA VERA: A THOROUGH QT/QTC STUDY IN HEALTHY SUBJECTS

EHA Library, Nishit Modi, 421638

PLATELET PARAMETERS AND THEIR ROLE IN MYELOPROLIFERATIVE NEOPLASMS, THROMBOCYTOPENIA AND MYELODYSPLASTIC SYNDROME

EHA Library, Soon Hee Chang, 421639

PHASE 2 STUDY EVALUATING EFFICACY AND SAFETY OF SELINEXOR MONOTHERAPY IN PATIENTS WITH JAKI-NAÏVE MYELOFIBROSIS AND MODERATE THROMBOCYTOPENIA

EHA Library, Joseph M Scandura, 421640

AN OPEN-LABEL PHASE 3 STUDY OF BOMEDEMSTAT, A LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) INHIBITOR, FOR ESSENTIAL THROMBOCYTHEMIA

EHA Library, Ilya Kirgner, 421641

FIVE-YEAR NET SURVIVAL OF MYELOID NEOPLASMS: A POPULATION-BASED STUDY IN SPAIN (2002-2016)

EHA Library, rafael marcos-gragera, 421642

ASSESSING CLINICAL PREDICTORS OF ANEMIA IN MYELOFIBROSIS AND THE POTENTIAL ROLE FOR MOMELOTINIB AT A MULTI-ETHNIC INNER-CITY CENTER

EHA Library, Josette Kamel, 421643

FIRST EXPERIENCE WITH MOMELOTINIB IN A REAL-WORLD SETTING: A COHORT ANALYSIS FROM THE AGMT STUDY GROUP

EHA Library, Thomas Melchardt, 421644

JAK INHIBITORS FOR MYELOFIBROSIS: UNCOVERING CLINICAL GAPS IN PHYSICIAN KNOWLEDGE AND PRACTICE

EHA Library, Victoria Harvey-Jones, 421645

EXPLORING REAL-WORLD APPLICATIONS OF ROPEGINTERFERON IN POLYCYTHEMIA VERA

EHA Library, Novella Pugliese, 421646

CLINICAL FEATURES AND NEXT-GENERATION SEQUENCING LANDSCAPE OF POLYCYTHEMIA VERA AND IDIOPATHIC ERYTHROCYTOSIS: A CHINESE MONOCENTRIC RETROSPECTIVE STUDY

EHA Library, JIAN HUANG, 421647

EFFICACY AND SAFETY OF MIDOSTAURIN THERAPY IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: A SINGLE CENTER EXPERIENCE.

EHA Library, Agata Ogłoza, 421648

PRELIMINARY, SINGLE CENTER, REAL WORLD SAFETY AND EFFICACY DATA FROM THE TREATMENT OF MYELOFIBROSIS PATIENTS WITH MOMELOTINIB

EHA Library, Maria Dimou, 421649

ELEVATED VITAMIN B12 LEVELS IN MYELOPROLIFERATIVE NEOPLASMS: A COMPREHENSIVE ANALYSIS ON PREVALENCE, PROGNOSTIC SIGNIFICANCE AND TREATMENT RESPONSE

EHA Library, Shehab Fareed Abdelgabber, 421650

TIMING OF ALLO-HSCT IN CHRONIC MYELOMONOCYTIC LEUKEMIAS - A CHINESE REAL-WORLD STUDY

EHA Library, Jin Zhang, 421651

EFFICACY AND SAFETY OF MEPOLIZUMAB FOR THE TREATMENT OF PDGFRΑ-NEGATIVE HYPEREOSINOPHILIC SYNDROME: A SINGLE-CENTRE CONSECUTIVE CASE STUDY.

EHA Library, Carlota Portocarrero de las Heras Pérez, 421652

CONSENSUS-BASED BEST PRACTICE RECOMMENDATIONS FOR MF MANAGEMENT IN ROUTINE CLINICAL PRACTICE: SYSTEMATIC LITERATURE REVIEW AND CLINICAL PRACTICE RECOMMENDATIONS FROM AN ASIA-PACIFIC PERSPECTIVE

EHA Library, Harinder Gill, 421653

ESSENTIAL THROMBOCYTHEMIA: CLINICAL CHARACTERISTICS, DIAGNOSTIC CHALLENGES AND THERAPEUTIC APPROACHES

EHA Library, cheybi ameni, 421654

IMPACT OF LABORATORY MARKERS AND CARDIOVASCULAR RISK FACTORS ON THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA

EHA Library, Marina Dokic, 421655

ANEMIA AND TRANSFUSION REQUIREMENT IN PATIENTS WITH MYELOFIBROSIS – A SINGLE CENTER EXPERIENCE

EHA Library, Ivanka Percic, 421656

AN OPEN-LABEL PHASE 2 STUDY OF BOMEDEMSTAT, A LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) INHIBITOR, FOR THE TREATMENT OF POLYCYTHEMIA VERA

EHA Library, Lindsay Rein, 421657

SUMMIT PART 2 TRIAL IN PROGRESS: A GLOBAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-PART PHASE 2 CLINICAL TRIAL OF BEZUCLASTINIB IN ADULT PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS

EHA Library, Andreas Reiter, 421658

ASSISTED REPRODUCTIVE TECHNOLOGY IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA:  A NEW CLINICAL CHALLENGE

EHA Library, Cristina Bucelli, 421659

SKIN INVOLVEMENT PREDICTS SYMPTOMATIC BURDEN IN INDOLENT SYSTEMIC MASTOCYTOSIS - REPORT FROM A NATIONAL SURVEY IN PORTUGAL

EHA Library, Christopher J. Saunders, 421660

EFFICACY AND SAFETY OF PEGYLATED INTERFERON ALFHA-2B THERAPY IN POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA IN THE REAL WORLD

EHA Library, Yueyue Zheng, 421661

RUXOLITINIB IN PATIENTS WITH POLYCYTHAEMIA VERA: FINDINGS FROM A MANAGED ACCESS PROGRAM

EHA Library, Thirupathi Pattipaka, 421662

PREDICTIVE FACTORS FOR THE EFFECTIVENESS OF TARGET THERAPY FOR MYELOFIBROSIS

EHA Library, Olga Vinogradova, 421663

REAL-WORLD EFFICACY AND SAFETY OF RUXOLITINIB IN THE TREATMENT OF ELDERLY MYELOFIBROSIS PATIENTS: A RETROSPECTIVE STUDY

EHA Library, Xiaohan Liu, 421664

HOVON 172: TASQFORCE; A PHASE 1B/2 TRIAL WITH TASQUINIMOD IN PATIENTS WITH MYELOFIBROSIS (PRIMARY, POST-PV OR POST-ET) REFRACTORY TO OR INTOLERANT FOR JAK2 INHIBITION

EHA Library, Peter te Boekhorst, 421665

RUXOLITINIB-AZACITIDINE COMBINATION THERAPY FOR ACCELERATED-PHASE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Fatma Keklik Karadag, 421666

PROMISE: INVESTIGATION INTO THE COMBINATION OF PLX2853 WITH RUXOLITINIB IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS NOT RECEIVING AN ADEQUATE RESPONSE WITH RUXOLITINIB ALONE

EHA Library, Adam Mead, 421667

RETROSPECTIVE ANALYSIS OF RUXOLITINIB TREATMENT IN MYELOPROLIFERATIVE DISORDERS

EHA Library, Guillermo Haces Tirado, 421668

CAROTID INTIMAL THICKNESS SCREENING IN MYELOPROLIFERATIVE NEOPLASM PATIENTS AGED YOUNGER THAN 60 YEARS

EHA Library, Sara El-sayed, 421669

RESULTS OF TARGETED THERAPY OF ADVANCED SYSTEMIC MASTOCYTOSIS IN REAL CLINICAL PRACTICE: SINGLE CENTER EXPERIENCE

EHA Library, Dzhariyat Shikhbabaeva, 421670

APEX PART 2 TRIAL IN PROGRESS: A RANDOMIZED, PHASE 2 OPEN-LABEL CLINICAL STUDY OF BEZUCLASTINIB IN ADULT PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS

EHA Library, Khalid Shoumariyeh, 421671

CLASSIC HODGKIN LYMPHOMA IN CHILDREN AT THE TUNISIAN CENTER

EHA Library, amira guizeni, 421672

QUANTITATIVE PET PARAMETERS ON BASELINE AND INTERIM FDG-PET SCANS IN HODGKIN LYMPHOMA AS A PROGNOSTIC MARKER

EHA Library, Sze Ting Lee, 421673

EXPRESSION PATTERNS OF GATA3 IN CLASSICAL HODGKIN LYMPHOMA. A CLINICO- PATHOLOGICAL STUDY

EHA Library, Andreas Epameinondas Koumpis, 421674

CLINICAL CHARACTERISTICS AND OUTCOME ASSOCIATED WITH THE EXPRESSION OF NEUTROPHIL EXTRACELLULAR TRAPS MARKERS IN NEWLY DIAGNOSED CLASSIC HODGKIN LYMPHOMA.

EHA Library, Chantiya Chanswangphuwana, 421675

THERAPEUTIC RESULTS OF A TUNISIAN PROSPECTIVE NON-RANDOMIZED ADULT HODGKIN LYMPHOMA STUDY: A SINGLE-INSTITUTION EXPERIENCE ABOUT 114 ADULT PATIENTS.

EHA Library, Khouloud Mezghani, 421676

EVALUATING EFFICACY OF NON-DOXORUBICIN AND DOXORUBICIN-BASED CHEMOTHERAPY REGIMENS IN SEVERELY G6PD DEFICIENT HODGKIN LYMPHOMA PATIENTS IN BAHRAIN

EHA Library, Fatima Sabri, 421677

EFFECT OF ONLINE EDUCATION ACTIVITY ON HEMATOLOGIST/ONCOLOGISTS’ ABILITY TO TREAT PATIENTS WITH IMMUNOTHERAPY FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA

EHA Library, Victoria Harvey-Jones, 421678

SINGLE-CENTER EXPERIENCE OF NIVOLUMAB USE FOR REFRACTORY/RELAPSED LYMPHOMA PATIENTS IN LIMITED RESOURCES AREA

EHA Library, Lusine Harutyunyan, 421679

THE ROLE OF 18FDG PET-CT IN THE INITIAL STAGING OF HODGKIN'S LYMPHOMA: INSIGHTS FROM MONASTIR, TUNISIA

EHA Library, Kmar Mrad, 421680

PRELIMINARY RESULTS OF THE PHASE 2 STUDY EVALUATING THE SAFETY AND EFFICACY OF PEMBROLIZUMAB (KEYTRUDA) WITH BENDAMUSTINE (TREANDA) IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA (KESTREL-01)

EHA Library, Chathuri Abeyakoon, 421681

WITH NEW DRUGS COMES NEW COMPLICATIONS: NIVOLUMAB INDUCED ACQUIRED HEMOPHILIA A AND HLH IN HODGKIN LYMPHOMA SUCCESSFULLY TREATED WITH RITUXIMAB AND STEROIDS

EHA Library, Sachin Bansal, 421682

MOBILIZATION AND HARVEST OF STEM CELLS AFTER SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA

EHA Library, Anatoly Uss, 421683

DESENSITIZATION TO BRENTUXIMAB VEDOTIN AFTER ANAPHYLAXIS IN HODGKIN'S LYMPHOMA

EHA Library, Rahma Belhadj Jrad, 421684

THERAPEUTIC OUTCOMES OF TUNISIAN PROTOCOLS USED IN ADULTS WITH BULKY MEDIASTINAL HODGKIN LYMPHOMA

EHA Library, Khouloud Mezghani, 421685

BENDAMUSTINE COMBINED WITH BRENTUXIMAB VEDOTIN FOR THE TREATMENT OF RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA

EHA Library, Rahma Belhadj Jrad, 421686

HODGKIN LYMPHOMA PRESENTING AS A TWELVE-YEAR OLD CERVICAL ADENOPATHIC CONGLOMERATE

EHA Library, Juan Eirís del Río, 421687

DOES THE ADDITION OF BRENTUXIMAB VEDOTIN TO SALVAGE THERAPY BEFORE TRANSPLANTATION AFFECT TRANSPLANT SUCCESS IN HODGKIN LYMPHOMA PATIENTS ? SINGLE CENTRE, PRELIMINARY RESULTS

EHA Library, Taner Tan, 421688

LACK OF PROGNOSTIC IMPACT OF RISK GROUPS IN PATIENTS WITH HODGKIN LYMPHOMA (HL) TREATED WITH ESCALATED BEACOPP - LONG TERM FOLLOW-UP OF A SINGLE CENTER EXPERIENCE

EHA Library, Igor Aurer, 421689

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HODGKIN LYMPHOMA RESPONSIVE TO PD-1 BLOCKADE: A REAL-WORLD ANALYSIS OF THE “RETE EMATOLOGICA PUGLIESE” (REP)

EHA Library, Francesco Gaudio, 421690

REAL WORLD EXPERIENCE OF HODGKIN LYMPHOMA IN A TERTIARY CARE CENTRE IN NORTH INDIA

EHA Library, Tejasvini Vaid, 421691

OPEN-LABEL PHASE 1 STUDY TO EVALUATE SAFETY OF SGN-35C IN ADULTS WITH SELECT RELAPSED/REFRACTORY LYMPHOMAS (SGN35C-001; TRIAL IN PROGRESS)

EHA Library, Swetha Kambhampati, 421692

BEACOPP-R REGIMEN TOXICITY IN HODGKIN LYMPHOMA PATIENTS: A TUNISIAN RETROSPECTIVE UNICENTRIC STUDY.

EHA Library, Khouloud Mezghani, 421693

ROLE OF 18 FDG PET/CT IN THE INITIAL STAGING AND MANAGEMENT OF PATIENTS WITH HODGKIN'S LYMPHOMA: A SINGLE-CENTER STUDY IN THE CLINICAL HEMATOLOGY DEPARTMENT OF MONASTIR

EHA Library, yasmine bnouni, 421694

SERUM IGM LEVELS AT DIAGNOSIS OF PATIENTS WITH HODGKIN LYMPHOMA (HL): CORRELATIONS WITH CLINICOPATHOLOGICAL FEATURES AND OUTCOMES

EHA Library, Theodoros Vassilakopoulos, 421695

KEYFORM-008: A PHASE 3 STUDY OF COFORMULATED FAVEZELIMAB AND PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA REFRACTORY TO ANTI–PD-1 THERAPY

EHA Library, David Lavie, 421696

PET-GUIDED DE-ESCALATION STRATEGY IN THE TREATMENT OF ADVANCED STAGE HODGKIN LYMPHOMA: A SINGLE MOROCCAN CENTER RETROSPECTIVE COMPARISON

EHA Library, Mahtat EL MEHDI, 421697

OUTCOME OF LYMPHADENOPATHY WITH NORMAL BLOOD COUNTS IN CHILDREN, SINGLE CENTRE EXPERIENCE.

EHA Library, Menna Shamma, 421698

OUTCOMES OF TREATMENT FOR PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AND THE ROLE OF PET-CT: A MONOCENTRIC STUDY.

EHA Library, rihab ben sghaier, 421699

INTERACTION OF CYTOCHROME P450 GENES AND THEIR CONTRIBUTION TO THE DEVELOPMENT OF HEMATOLOGICAL TOXICITY OF PROGRAM CHEMOTHERAPY IN PATIENTS WITH HODGKIN LYMPHOMA

EHA Library, Yana Shebunyaeva, 421700

PRELIMINARY RESULTS OF THE USE OF BRENTUXIMAB VEDOTIN WITH ICE IN SECOND LINE THERAPY FOR REFRACTORY/RELAPSING HODGKIN LYMPHOMA WITH AUTO-HSCT, IN THE GROUP OF PATIENTS WITH UNFAVORABLE PROGNOSIS.

EHA Library, Saule Gabbassova, 421701

(BETA-2 MICROGLOBULINE) SERUM LEVELS AND PREDICTION OF RESPONSE IN INFLAMED LYMPHOMAS WITH PD-1/PD-L1 CO-EXPRESSION TREATED WITH STANDARD CHEMOTHERAPY PLUS ANTI-PD-1

EHA Library, Maher Salamoon, 421702

REAL-LIFE TREATMENT PRACTICE AND CLINICAL OUTCOMES IN EGYPTIAN CLASSICAL HODGKIN LYMPHOMA PATIENTS: THE PROFILE STUDY

EHA Library, Hamdy A. Azim, 421703

CLINICAL PROFILE AND TREATMENT OUTCOME OF LYMPHOPLASMACYTIC LEUKEMIA (LPL) IN CURRENT ERA- A RETROSPECTIVE ANALYSIS FROM A TERTIARY CARE CENTER

EHA Library, Nitin Gupta, 421704

A 5 YEAR RETROSPECTIVE STUDY OF T-CELL LYMPHOMA  IN ALBANIA

EHA Library, Alma Cili, 421705

THE DIAGNOSTIC VALUE OF LYMPH NODE FLOW IMMUNOTYPING IN LYMPHOMA

EHA Library, Lian Li, 421706

MANTLE CELL LYMPHOMA : DIAGNOSIS AND THERAPEUTIC ASPECTS IN  SOUTHERN TUNISIA

EHA Library, Rim Ferhi, 421707

RETROSPECTIVE STUDY TO DESCRIBE REAL-WORLD TREATMENT PATTERNS AND ASSOCIATED OUTCOMES OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) FROM THE C3I LYMPHOMA REGISTRY IN QUEBEC

EHA Library, Isabelle Fleury, 421708

MARGINAL ZONE LYMPHOMA: AN IRISH SINGLE INSTITUTION EXPERIENCE

EHA Library, Tushar Pramod, 421709

COMPARISON OF CLINICAL FEATURES AND MANAGEMENT BETWEEN CHINESE NON-IGM LPL AND WM PATIENTS

EHA Library, Yan Li, 421710

EXAMINATION AND TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA IN ST. PETERSBURG (RUSSIA): DATA FROM REAL-LIFE CLINICAL PRACTICE

EHA Library, Evgenii Kunevich, 421711

IMPACT OF PROGRESSION OF DISEASE WITHIN 24 MONTHS (POD24) ON FOLLICULAR LYMPHOMA TREATMENT OUTCOME. A SINGLE CENTRE RETROSPECTIVE STUDY

EHA Library, Alfred Jones, 421712

CHANGES IN T CELL SUBSETS DURING TREATMENTS ASSOCIATED WITH OUTCOMES IN NEWLY DIAGNOSED FOLLICULAR LYMPHOMA

EHA Library, Zhijuan Lin, 421713

CD38 EXPRESSION AS AN ADDITIONAL PROGNOSTIC MARKER IN MANTLE CELL LYMPHOMA.

EHA Library, MATTEO D'ADDONA, 421714

OUTCOME OF MANTLE CELL LYMPHOMA WITH UNIFORM PROTOCOL : A NORTH INDIAN TERTIARY CARE CENTER EXPERIENCE

EHA Library, Soumyadeep Datta, 421715

RESULTS OF THERAPY FOR BCL2-R+ AND BCL2-R- FOLLICULAR LYMPHOMA

EHA Library, Ekaterina Nesterova, 421716

”REAL-LIFE” DATA OF ZANUBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA - A MULTI-CENTER RETROSPECTIVE STUDY

EHA Library, Gilad Itchaki, 421717

EXPLORING THE PROGNOSTIC VALUE OF BIOLOGICAL BIOMARKERS NLR AND PLR IN NODAL MANTLE CELL LYMPHOMA

EHA Library, Victor Tomacinschii, 421718

RISK FACTORS AND TREATMENT STRATEGIES OF NON-TRAUMATIC CHYLOTHORAX IN FOLLICULAR LYMPHOMA - A CASE SERIES

EHA Library, Thomas Weber, 421719

BGB-11417-203, AN ONGOING, PHASE 2 STUDY OF SONROTOCLAX (BGB-11417), A NEXT-GENERATION BCL2 INHIBITOR, IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA

EHA Library, Jeffrey Matous, 421720

EPCORE FL-2: PHASE 3 TRIAL OF EPCORITAMAB WITH RITUXIMAB AND LENALIDOMIDE (R2) VS CHEMOIMMUNOTHERAPY OR R2 IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA

EHA Library, Kim Linton, 421721

WAVELINE-006: A PHASE 2 STUDY OF ZILOVERTAMAB VEDOTIN (ZV) ALONE OR IN COMBINATION WITH NEMTABRUTINIB AS SUBSEQUENT-LINE THERAPY IN AGGRESSIVE AND INDOLENT B-CELL MALIGNANCIES

EHA Library, Wojciech Jurczak, 421722

CHIDAMIDE IN COMBINATION WITH R-CHOP FOR NEWLY DIAGNOSED B‑CELL NON-HODGKIN LYMPHOMA WITH EPIGENETIC MUTATIONS: PRELIMINARY ANALYSIS FROM THE RESULTS OF A PHASE II STUDY

EHA Library, Hongmei Jing, 421723

ASSOCIATION OF ATG16L1 RS2241880 AND TP53 RS1042522 WITH CHARACTERISTICS AND COURSE OF DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Andjelina Zivanovic, 421724

QUANTITATIVE SYSTEMS PHARMACOLOGY MODELING OF LONCASTUXIMAB TESIRINE COMBINED WITH MOSUNETUZUMAB AND GLOFITAMAB HELPS GUIDE DOSING FOR PATIENTS WITH DLBCL

EHA Library, Yuezhe Li, 421725

PROGNOSTIC ROLE OF NUTRITION-RELATED FACTORS IN PRIMARY GASTROINTESTINAL DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Qiqi Qiao, 421726

INCIDENCE OF SECOND PRIMARY MALIGNANCIES (SPM) FOLLOWING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY (CAR-T)

EHA Library, Charles Pei, 421727

COMPARISON OF DIFFERENT PROGNOSTIC MODELS FOR ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA: REAL-WORLD DATA FROM T CELL LYMPHOMA COOPERATION GROUP IN SOUTH CHINA

EHA Library, Qiuyuan Xiang, 421728

PHASE II STUDY OF ORELABRUTINIB, RITUXIMAB AND THIOTEPA (ORT) COMBINED WITH OR WITHOUT HIGH-DOSE MTX THERAPY IN PATIENTS WITH PRIMARY CNS LYMPHOMA

EHA Library, Chunmei Yang, 421730

AI-ASSISTED DIAGNOSIS OF DIFFUSE LARGE B-CELL LYMPHOMA WITH BONE MARROW INVASION

EHA Library, Xuelian Wu, 421731

QUANTITATIVE SYSTEMS PHARMACOLOGY MODEL PREDICTS COMBINATION ACTIVITY OF CD19-TARGETED LONCASTUXIMAB TESIRINE CO-DOSED WITH A CD20/CD3 T-CELL BISPECIFIC (EPCORITAMAB) IN DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Yuezhe Li, 421732

A FIRST-IN-HUMAN STUDY OF THE POTENT AND HIGHLY SELECTIVE BTK DEGRADER ABBV-101 IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES

EHA Library, William Wierda, 421734

CNS PROPHYLAXIS, TREATMENT & OUTCOMES IN HIGH GRADE NON-HODGKIN'S LYMPHOMA: AN EIGHT-YEAR EXPERIENCE

EHA Library, Inova Lee, 421735

PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA WHO ARE POTENTIAL CANDIDATES FOR CAR T-CELL THERAPY

EHA Library, ANNA HIRATSUKA, 421736

OUTCOMES IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‑CELL LYMPHOMA (DLBCL) TREATED WITH SYSTEMIC THERAPY FROM REAL‑WORLD EXPERIENCE (ORCHID) STUDY

EHA Library, Catherine Thieblemont, 421737

EVALUATION OF FERTILITY IN WOMEN TREATED WITH THE R-DA-EPOCH REGIMEN FOR PRIMARY MEDIASTINAL B CELL LYMPHOMA (PMBCL)

EHA Library, ANGELIKI GEORGOPOULOU, 421738